Retractable Q3 Sales Jump 40% but Gross Profit Collapses to $193K; Controls Still Not Effective
RVP is trading near its 52-week low of $0.53 (4.2% above the low).
Summary
Retractable's Q3 sales rose 40% to $14.1M but gross profit collapsed to $193K as low-margin needle sales dominated the mix. Nine-month operating losses widened to $15.5M, cash fell to $1.89M, and management again concluded its controls were not effective.
Key Events · Earnings and Guidance · RVP
-
Q3 Sales Up 40%, Gross Profit Collapses
Net sales rose to $14,128,245 from $10,085,723, but cost of sales jumped 69.9% to $13,934,998, cutting gross profit to $193,247 from $1,685,904.
-
Nine-Month Operating Loss Widens
Loss from operations was $15,453,918 versus $13,461,632 a year earlier; the net loss narrowed to $3,754,042 only because of a $6,366,466 realized gain on equity sales.
-
Cash Falls, Portfolio Funds Operations
Cash and equivalents dropped to $1,890,914 from $2,588,625 at December 31, 2025, with $37,352,432 held in debt and mutual fund securities available to fund operations.
-
Controls Deemed Not Effective
Management concluded disclosure controls and procedures were not effective as of September 30, 2026, with previously reported material weaknesses still being remediated.
Analysis · RVP · Industrial Applications And Services
Revenue growth is real but unprofitable: Q3 net sales rose 40.1% to $14.1M while cost of sales rose 69.9%, leaving gross profit of just $193,247 versus $1,685,904 a year earlier. The mix shifted toward lower-priced EasyPoint needles, so more units shipped without more money. The nine-month picture is worse at the operating line — a $15.5M operating loss versus $13.5M — and only looks better at the bottom because of a one-time $6.4M realized gain on selling equity investments. Cash is down to $1.89M from $2.59M, with the company leaning on a $37.4M investment portfolio to fund operations. Management also concluded disclosure controls were not effective, with previously reported material weaknesses still being remediated. Against that, the CEO has a 10b5-1 plan to buy up to $800,000 of stock starting November 18, 2026 — a real-money purchase signal from the top, though small relative to the operating problems.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RVP was trading at $0.55 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $16.7M. The 52-week trading range was $0.53 to $0.87. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.